ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy
Cancer Cell International,
Abstract Despite advancements in treating metastatic melanoma, many patients exhibit resistance to targeted therapies.